Evidence map›Paper›PMID 41824115›Full record

ArticleMolecular biology reports2026

Enzalutamide effectively inhibits the growth of meningiomas via p21-dependent senescence induction.

Thanawat Trasaktaweesakul, Pundit Asavaritikrai, Phattrara Khuansonthi, Pitchanun Jaturutthaweechot, Nopporn Naewwan, Krajang Talabnin, Chutima Talabnin

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Thanawat TrasaktaweesakulSchool of Translational Medicine, Institute of Medicine, Suranaree University of Technology, Nakhon Ratchasima, 30000, Thailand.
Pundit AsavaritikraiSchool of Surgery, Institute of Medicine, Suranaree University of Technology, Nakhon Ratchasima, 30000, Thailand.
Phattrara KhuansonthiSchool of Surgery, Institute of Medicine, Suranaree University of Technology, Nakhon Ratchasima, 30000, Thailand.
Pitchanun JaturutthaweechotSchool of Chemistry, Institute of Science, Suranaree University of Technology, Nakhon Ratchasima, 30000, Thailand.
Nopporn NaewwanSchool of Translational Medicine, Institute of Medicine, Suranaree University of Technology, Nakhon Ratchasima, 30000, Thailand.
Krajang TalabninSchool of Pathology, Institute of Medicine, Suranaree University of Technology, Nakhon Ratchasima, 30000, Thailand. Krajang.t@sut.ac.th.
Chutima TalabninSchool of Chemistry, Institute of Science, Suranaree University of Technology, Nakhon Ratchasima, 30000, Thailand. chutima.sub@sut.ac.th.

Funding

National Science, Research, and Innovation Fund 195616
6 · The paper itself

Abstract

backgroundMeningiomas are the most common central nervous system tumors and are primarily managed through surgical resection and radiation therapy. The development of meningioma is associated with sex steroid hormone-related risk factors. However, anti-sex steroid hormone therapy in meningiomas is still unclear.

methodsExpression levels of sex steroid hormone receptors were determined in meningioma tissues and cell lines via quantitative PCR. The effects of androgen receptor inhibitor (enzalutamide; ENZ) on meningioma cell growth were investigated via cell viability test, cell cycle analysis and senescence-associated β-galactosidase activity.

resultsAndrogen receptor (AR) expression was observed in all WHO grade meningiomas. In comparison, progesterone receptor (PR) expression was detected mainly in WHO grade 1 meningiomas but was absent in grade 3 meningiomas. Targeting AR with ENZ significantly inhibited the growth of malignant meningioma cells (HKBMM and IOMM-Lee). Malignant meningioma cells, particularly IOMM-Lee cells, were sensitive to ENZ. ENZ induced cell cycle arrest and increased the sub-G1 population in both malignant meningioma cell lines. Elevated cyclin D1 expression and loss of replicative potential via the reduction of Ki-67 nuclei were also observed. ENZ induced senescence-associated β-galactosidase activity, associated with up-regulation of p21 and down-regulation of the anti-apoptotic protein Mcl-1, in both malignant meningioma cell lines. Additionally, down-regulation of AR-positive cells and AR target genes, including EDN2, TMPRSS2, and KLK3, was observed only in HKBMM cells expressing AR.

conclusionsOur findings suggest that ENZ induces a senescence-like phenotype in malignant meningioma cells via p21-dependent induction. Lastly, ENZ may serve as a promising targeted therapy for meningiomas, particularly for aggressive subtypes or in cases of recurrence.

Indexed as

Cyclin-Dependent Kinase Inhibitor p21Meningeal NeoplasmsMeningiomaPhenylthiohydantoinBenzamidesCell Cycle CheckpointsCell Line, TumorCell ProliferationCell SurvivalCellular SenescenceFemaleGene Expression Regulation, NeoplasticHumansMaleNitrilesReceptors, AndrogenBenzamidesCDKN1A protein, humanCyclin-Dependent Kinase Inhibitor p21enzalutamideNitrilesPhenylthiohydantoinReceptors, AndrogenAndrogen receptorsEnzalutamideMeningiomasP21P53Senescence-like phenotype

Identifiers

PMID41824115

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.